(HG) Hamilton Insurance - Overview
Exchange: NYSE •
Country: Bermuda •
Currency: USD •
Type: Common Stock •
ISIN: BMG427061046
Stock: Casualty Reinsurance, Property Reinsurance, Specialty Reinsurance, Insurance
Total Rating 62
Risk 69
Buy Signal 0.35
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 27.7% |
| Relative Tail Risk | -8.81% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.48 |
| Alpha | 48.75 |
| Character TTM | |
|---|---|
| Beta | 0.488 |
| Beta Downside | 0.724 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.07% |
| CAGR/Max DD | 1.70 |
Description: HG Hamilton Insurance January 13, 2026
Hamilton Insurance Group, Ltd. (NYSE: HG) is a Bermuda-based specialty insurer and reinsurer that operates three underwriting platforms-Hamilton Global Specialty, Hamilton Select, and Hamilton Re-offering a broad suite of casualty, property, and niche reinsurance products across commercial auto, healthcare, aviation, cyber, and political-risk lines, among others.
Since its 2013 incorporation, the firm has focused on high-margin, low-frequency risks such as space, kidnap-and-ransom, and environmental liability, positioning itself to benefit from the industry-wide shift toward “hard-price” cycles driven by rising reinsurance rates and tighter capacity. As of the most recent filing, HG reported net written premiums of approximately $1.1 billion and a combined ratio of 93%, indicating underwriting profitability despite elevated catastrophe exposure.
Investors should note that HG’s capital strength (RBC ratio ≈ 1.5×) and its diversified global portfolio make it relatively resilient to interest-rate volatility, a key driver for reinsurers’ investment income. For a deeper, data-driven view of Hamilton’s valuation metrics, a quick look at ValueRay’s analyst tools can help surface any hidden upside.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 438.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.52 > 1.0 |
| NWC/Revenue: 22.09% < 20% (prev 47.92%; Δ -25.84% < -1%) |
| CFO/TA 0.09 > 3% & CFO 833.0m > Net Income 438.4m |
| Net Debt (-805.4m) to EBITDA (749.1m): -1.08 < 3 |
| Current Ratio: 2.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (101.5m) vs 12m ago -0.45% < -2% |
| Gross Margin: 37.25% > 18% (prev 0.48%; Δ 3676 % > 0.5%) |
| Asset Turnover: 32.87% > 50% (prev 23.55%; Δ 9.33% > 0%) |
| Interest Coverage Ratio: 35.24 > 6 (EBITDA TTM 749.1m / Interest Expense TTM 20.8m) |
Altman Z'' 1.81
| A: 0.07 (Total Current Assets 1.07b - Total Current Liabilities 446.6m) / Total Assets 9.21b |
| B: 0.17 (Retained Earnings 1.53b / Total Assets 9.21b) |
| C: 0.09 (EBIT TTM 732.7m / Avg Total Assets 8.52b) |
| D: 0.24 (Book Value of Equity 1.53b / Total Liabilities 6.47b) |
| Altman-Z'' Score: 1.81 = BBB |
Beneish M -2.60
| DSRI: 0.72 (Receivables 2.48b/2.26b, Revenue 2.80b/1.84b) |
| GMI: 1.30 (GM 37.25% / 48.33%) |
| AQI: 1.10 (AQ_t 0.88 / AQ_t-1 0.80) |
| SGI: 1.52 (Revenue 2.80b / 1.84b) |
| TATA: -0.04 (NI 438.4m - CFO 833.0m) / TA 9.21b) |
| Beneish M-Score: -2.60 (Cap -4..+1) = A |
What is the price of HG shares?
As of February 10, 2026, the stock is trading at USD 29.70 with a total of 467,999 shares traded.
Over the past week, the price has changed by +6.80%, over one month by +10.33%, over three months by +13.10% and over the past year by +58.06%.
Over the past week, the price has changed by +6.80%, over one month by +10.33%, over three months by +13.10% and over the past year by +58.06%.
Is HG a buy, sell or hold?
Hamilton Insurance has received a consensus analysts rating of 3.83.
Therefore, it is recommended to buy HG.
- StrongBuy: 1
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.1 | 1.2% |
| Analysts Target Price | 30.1 | 1.2% |
| ValueRay Target Price | 36.5 | 23% |
HG Fundamental Data Overview February 09, 2026
P/E Trailing = 7.0379
P/S = 1.0756
P/B = 1.0974
Revenue TTM = 2.80b USD
EBIT TTM = 732.7m USD
EBITDA TTM = 749.1m USD
Long Term Debt = 149.7m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 149.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -805.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.15b USD (2.95b + Debt 149.7m - CCE 955.1m)
Interest Coverage Ratio = 35.24 (Ebit TTM 732.7m / Interest Expense TTM 20.8m)
EV/FCF = 2.58x (Enterprise Value 2.15b / FCF TTM 833.0m)
FCF Yield = 38.79% (FCF TTM 833.0m / Enterprise Value 2.15b)
FCF Margin = 29.74% (FCF TTM 833.0m / Revenue TTM 2.80b)
Net Margin = 15.65% (Net Income TTM 438.4m / Revenue TTM 2.80b)
Gross Margin = 37.25% ((Revenue TTM 2.80b - Cost of Revenue TTM 1.76b) / Revenue TTM)
Gross Margin QoQ = 38.67% (prev 46.13%)
Tobins Q-Ratio = 0.23 (Enterprise Value 2.15b / Total Assets 9.21b)
Interest Expense / Debt = 3.29% (Interest Expense 4.93m / Debt 149.7m)
Taxrate = 2.14% (3.87m / 180.3m)
NOPAT = 717.0m (EBIT 732.7m * (1 - 2.14%))
Current Ratio = 2.38 (Total Current Assets 1.07b / Total Current Liabilities 446.6m)
Debt / Equity = 0.06 (Debt 149.7m / totalStockholderEquity, last quarter 2.66b)
Debt / EBITDA = -1.08 (Net Debt -805.4m / EBITDA 749.1m)
Debt / FCF = -0.97 (Net Debt -805.4m / FCF TTM 833.0m)
Total Stockholder Equity = 2.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.15% (Net Income 438.4m / Total Assets 9.21b)
RoE = 17.63% (Net Income TTM 438.4m / Total Stockholder Equity 2.49b)
RoCE = 27.79% (EBIT 732.7m / Capital Employed (Equity 2.49b + L.T.Debt 149.7m))
RoIC = 27.19% (NOPAT 717.0m / Invested Capital 2.64b)
WACC = 7.49% (E(2.95b)/V(3.10b) * Re(7.71%) + D(149.7m)/V(3.10b) * Rd(3.29%) * (1-Tc(0.02)))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.06%
[DCF Debug] Terminal Value 82.93% ; FCFF base≈704.1m ; Y1≈868.5m ; Y5≈1.48b
Fair Price DCF = 443.9 (EV 27.84b - Net Debt -805.4m = Equity 28.65b / Shares 64.5m; r=7.49% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -16.04 | EPS CAGR: -52.50% | SUE: -2.14 | # QB: 0
Revenue Correlation: 34.95 | Revenue CAGR: 31.47% | SUE: 2.04 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.26 | Chg30d=+0.021 | Revisions Net=+2 | Analysts=5
EPS next Year (2026-12-31): EPS=4.37 | Chg30d=+0.043 | Revisions Net=+3 | Growth EPS=+1.9% | Growth Revenue=-0.2%
P/S = 1.0756
P/B = 1.0974
Revenue TTM = 2.80b USD
EBIT TTM = 732.7m USD
EBITDA TTM = 749.1m USD
Long Term Debt = 149.7m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 149.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -805.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.15b USD (2.95b + Debt 149.7m - CCE 955.1m)
Interest Coverage Ratio = 35.24 (Ebit TTM 732.7m / Interest Expense TTM 20.8m)
EV/FCF = 2.58x (Enterprise Value 2.15b / FCF TTM 833.0m)
FCF Yield = 38.79% (FCF TTM 833.0m / Enterprise Value 2.15b)
FCF Margin = 29.74% (FCF TTM 833.0m / Revenue TTM 2.80b)
Net Margin = 15.65% (Net Income TTM 438.4m / Revenue TTM 2.80b)
Gross Margin = 37.25% ((Revenue TTM 2.80b - Cost of Revenue TTM 1.76b) / Revenue TTM)
Gross Margin QoQ = 38.67% (prev 46.13%)
Tobins Q-Ratio = 0.23 (Enterprise Value 2.15b / Total Assets 9.21b)
Interest Expense / Debt = 3.29% (Interest Expense 4.93m / Debt 149.7m)
Taxrate = 2.14% (3.87m / 180.3m)
NOPAT = 717.0m (EBIT 732.7m * (1 - 2.14%))
Current Ratio = 2.38 (Total Current Assets 1.07b / Total Current Liabilities 446.6m)
Debt / Equity = 0.06 (Debt 149.7m / totalStockholderEquity, last quarter 2.66b)
Debt / EBITDA = -1.08 (Net Debt -805.4m / EBITDA 749.1m)
Debt / FCF = -0.97 (Net Debt -805.4m / FCF TTM 833.0m)
Total Stockholder Equity = 2.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.15% (Net Income 438.4m / Total Assets 9.21b)
RoE = 17.63% (Net Income TTM 438.4m / Total Stockholder Equity 2.49b)
RoCE = 27.79% (EBIT 732.7m / Capital Employed (Equity 2.49b + L.T.Debt 149.7m))
RoIC = 27.19% (NOPAT 717.0m / Invested Capital 2.64b)
WACC = 7.49% (E(2.95b)/V(3.10b) * Re(7.71%) + D(149.7m)/V(3.10b) * Rd(3.29%) * (1-Tc(0.02)))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.06%
[DCF Debug] Terminal Value 82.93% ; FCFF base≈704.1m ; Y1≈868.5m ; Y5≈1.48b
Fair Price DCF = 443.9 (EV 27.84b - Net Debt -805.4m = Equity 28.65b / Shares 64.5m; r=7.49% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -16.04 | EPS CAGR: -52.50% | SUE: -2.14 | # QB: 0
Revenue Correlation: 34.95 | Revenue CAGR: 31.47% | SUE: 2.04 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.26 | Chg30d=+0.021 | Revisions Net=+2 | Analysts=5
EPS next Year (2026-12-31): EPS=4.37 | Chg30d=+0.043 | Revisions Net=+3 | Growth EPS=+1.9% | Growth Revenue=-0.2%